CHARLOTTE, N.C., April 27, 2005 (PRIMEZONE) -- SmallCapReview.com (www.SmallCapReview.com ), a leading small-cap stock information site, introduces Generex Biotechnology (Nasdaq:GNBT) to its database of subscribers and its website audience.
Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM).
The potential benefits are compelling, a pain-free, needle-free, noninvasive drug delivery. Dosages administered accurately and conveniently. An improved quality of life for people who currently depend on regular, painful injections to maintain their health.
To learn more about Generex Biotechnology please visit www.smallcapreview.com/gnbt.htm or visit the company's website at www.generex.com.
SmallCapReview.com news is a Free Newsletter sent to subscribers, highlighting select small-cap stocks. To sign-up visit www.smallcapreview.com/subscribe.htm. Features available at SmallCapReview.com include in-depth profiles of select Small-Cap and Penny Stocks, all-in-one message boards covering the top message board forums, an exhaustive research page, tech charts, and daily news on companies and trends in the small-cap market.
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this release include certain forward-looking statements, which are intended to be covered by safe harbors. Investors are cautioned that all forward-looking statements involve risks and uncertainties including, without limitation, the factors detailed from time to time in company filings with the Securities and Exchange Commission. These factors could affect businesses and financial results in the future and could cause actual results to differ materially from plans and projections. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by the company or any other person that objectives and plans will be achieved. All forward-looking statements made in this release are based on information presently available. We assume no obligation to update any forward-looking statements, except as required by law.
Disclosure: No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. SmallCapReview.com may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our website or within our reports. In order to be in full compliance with the Securities Act of 1933, Section 17(b), SmallCapReview.com will disclose in its disclaimer, what, if any compensation was received for our efforts in researching, presenting and disseminating this information to our subscriber database and featuring the report on our website. SmallCapReview.com has been compensated three thousand dollars by a third party for its efforts in presenting the Generex Biotechnology profile on its website and distributing it to its database of subscribers, this creates an inherent conflict of interest and readers are encouraged to view the full disclaimer at www.smallcapreview.com/gnbt.htm.